Details of Data Requests to Use Johnson and Johnson Data
Request listing updated daily
All Requests
The YODA Project posts proposals once data access has been granted or denied.
480 results returned displaying 1 to 10 of 480
Filters list
YODA Protocol Number
2022-5104
Product(s) of Interest REMICADE® (Infliximab) SIMPONI® (Golimumab) STELARA® (Ustekinumab)
No. Trials Provided 6
Product(s) of Interest REMICADE® (Infliximab) SIMPONI® (Golimumab) STELARA® (Ustekinumab)
No. Trials Provided 6
Published
Publications Available! See more below
Biomarkers for Predicting Long-term Outcomes in Ulcerative Colitis
Principal Investigator
Rirong ChenReports & Publications
Protocol & Associated Materials
Protocol #2022-5104 Proposal (PDF) Protocol #2022-5104 Review (PDF) Protocol #2022-5104 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4846
Product(s) of Interest ERLEADA® (Apalutamide)
No. Trials Provided 1
Product(s) of Interest ERLEADA® (Apalutamide)
No. Trials Provided 1
Ongoing
Publication Available!
External Validation of a Prognostic Model of Overall Survival In Men with Metastatic Castration-Resistant Prostate Cancer
Principal Investigator
Susan Halabi Duke UniversityReports & Publications
Protocol & Associated Materials
Protocol #2021-4846 Proposal (PDF) Protocol #2021-4846 Review (PDF) Protocol #2021-4846 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4822
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 2
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 2
Ongoing
Publication Available!
Comparative Efficacy of Ustekinumab and Infliximab on One Year Outcomes Among Biologic-nave Induction Responders in Crohn’s Disease
Principal Investigator
Neeraj NarulaReports & Publications
Cited By
View 9 CitationsProtocol & Associated Materials
Protocol #2021-4822 Proposal (PDF) Protocol #2021-4822 Review (PDF) Protocol #2021-4822 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4779
Product(s) of Interest REMICADE® (Infliximab) STELARA® (Ustekinumab) SIMPONI® (Golimumab)
No. Trials Provided 6
Product(s) of Interest REMICADE® (Infliximab) STELARA® (Ustekinumab) SIMPONI® (Golimumab)
No. Trials Provided 6
Published
Publications Available! See more below
Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease
Principal Investigator
Neeraj NarulaReports & Publications
Cited By
View 2 CitationsProtocol & Associated Materials
Protocol #2021-4779 Proposal (PDF) Protocol #2021-4779 Review (PDF) Protocol #2021-4779 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4778
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 3
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 3
Published
Publication Availible!
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease
Principal Investigator
Neeraj NarulaReports & Publications
Cited By
View 14 CitationsProtocol & Associated Materials
Protocol #2021-4778 Proposal (PDF) Protocol #2021-4778 Review (PDF) Protocol #2021-4778 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4757
Product(s) of Interest REMICADE® (Infliximab)
No. Trials Provided 2
Product(s) of Interest REMICADE® (Infliximab)
No. Trials Provided 2
Published
Publication Available!
A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis.
Principal Investigator
Neeraj Narula Hamilton Health SciencesReports & Publications
Protocol & Associated Materials
Protocol #2021-4757 Proposal (PDF) Protocol #2021-4757 Review (PDF) Protocol #2021-4757 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4684
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 3
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 3
Published
Publications Available!
Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease
Principal Investigator
Neeraj NarulaReports & Publications
Cited By
View 7 CitationsProtocol & Associated Materials
Protocol #2021-4684 Proposal (PDF) Protocol #2021-4684 Review (PDF) Protocol #2021-4684 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4637
Product(s) of Interest SPRAVATO® (Esketamine)
No. Trials Provided 3
Product(s) of Interest SPRAVATO® (Esketamine)
No. Trials Provided 3
Published
Publication Available!
Data-sharing and re-analysis for main studies assessed by the European Medicines Agency – a cross-sectional study on EPARs
Principal Investigator
Florian Naudet University of Rennes 1Reports & Publications
Protocol & Associated Materials
Protocol #2021-4637 Proposal (PDF) Protocol #2021-4637 Review (PDF) Protocol #2021-4637 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4602
Product(s) of Interest STELARA® (Ustekinumab) REMICADE® (Infliximab)
No. Trials Provided 4
Product(s) of Interest STELARA® (Ustekinumab) REMICADE® (Infliximab)
No. Trials Provided 4
Published
Publication Available!
Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s Disease
Principal Investigator
Neeraj NarulaReports & Publications
Cited By
View 5 CitationsProtocol & Associated Materials
Protocol #2021-4602 Proposal (PDF) Protocol #2021-4602 Review (PDF) Protocol #2021-4602 Due Diligence Assessment (PDF)
YODA Protocol Number
2021-4599
Product(s) of Interest DARZALEX® (Daratumumab)
No. Trials Provided 6
Product(s) of Interest DARZALEX® (Daratumumab)
No. Trials Provided 6
Published
Publication Available!